The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.

Published

Journal Article

Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function with inhaled corticosteroids.To evaluate potential biomarkers of predicting short-term (6-week) response to inhaled corticosteroid with subsequent evaluation of responders and nonresponders to asthma control over a longer interval (16 additional weeks).Eighty-three subjects with asthma off steroid were enrolled in this multicenter study. Biomarkers and asthma characteristics were evaluated as predictors of inhaled corticosteroid response over a 6-week trial for changes in FEV(1) and methacholine PC(20). After this, an additional 4-month trial evaluated asthma control.Although multiple baseline predictors had significant correlations with improvements for short-term inhaled steroid success, the only strong correlations (r >or= +/- 0.6) were albuterol reversibility (r = 0.83; P < .001), FEV(1)/forced vital capacity (r = -0.75; P < .001), and FEV(1) % predicted (r = -0.71; P < .001). Dividing the subjects in the short-term inhaled steroid trial into responders (>5% FEV(1) improvement) and nonresponders (

Full Text

Cited Authors

  • Martin, RJ; Szefler, SJ; King, TS; Kraft, M; Boushey, HA; Chinchilli, VM; Craig, TJ; Dimango, EA; Deykin, A; Fahy, JV; Israel, E; Lazarus, SC; Lemanske, RF; Leone, FT; Pesola, GR; Peters, SP; Sorkness, CA; Szwejbka, LA; Wechsler, ME; National Heart, Lung, and Blood Institute's Asthma Clinical Research Center,

Published Date

  • January 1, 2007

Published In

Volume / Issue

  • 119 / 1

Start / End Page

  • 73 - 80

PubMed ID

  • 17208587

Pubmed Central ID

  • 17208587

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

International Standard Serial Number (ISSN)

  • 0091-6749

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2006.10.035

Language

  • eng